Novartis AG expected to post earnings of $2.37 a share - Earnings Preview
Novartis AG
NOVN is expected to show a rise in quarterly revenue when it reports results on July 17 for the period ending June 30 2025
The Basel Basel-stadt-based company is expected to report a 13.3% increase in revenue to $14.181 billion from $12.51 billion a year ago, according to the mean estimate from 8 analysts, based on LSEG data. (Majority Sales represents Net Sales)
LSEG's mean analyst estimate for Novartis AG is for earnings of $2.37 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy," 14 "hold" and 4 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 1.1% in the last three months.
Wall Street's median 12-month price target for Novartis AG is CHF105.00, about 8.2% above its last closing price of CHF96.43
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 2.11 | 2.10 | 2.28 | Beat | 8.7 |
Dec. 31 2025 | 1.82 | 1.83 | 1.98 | Beat | 8.2 |
Sep. 30 2024 | 1.95 | 1.95 | 2.06 | Beat | 5.9 |
Jun. 30 2024 | 1.87 | 1.87 | 1.97 | Beat | 5.3 |
Mar. 31 2024 | 1.66 | 1.67 | 1.80 | Beat | 7.5 |
Dec. 31 2023 | 1.65 | 1.62 | 1.53 | Missed | -5.6 |
Sep. 30 2023 | 1.72 | 1.73 | 1.83 | Beat | 6 |
Jun. 30 2023 | 1.70 | 1.70 | 1.83 | Beat | 7.8 |
This summary was machine generated July 15 at 06:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)